Nowinski Cindy J, Siderowf Andrew, Simuni Tanya, Wortman Catherine, Moy Claudia, Cella David
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Mov Disord. 2016 May;31(5):725-33. doi: 10.1002/mds.26546. Epub 2016 Feb 26.
Neuro-QoL is a multidimensional patient-reported outcome measurement system assessing aspects of physical, mental, and social health identified by neurology patients and caregivers as important. One of the first neurology-specific patient-reported outcome measure systems created using modern test development methods, Neuro-Qol enables brief, yet precise, assessment and the ability to conduct both PD-specific and cross-disease comparisons. We present results of Neuro-QoL clinical validation using a sample of PD patients.
A total of 120 PD patients recruited from academic medical centers were assessed at baseline, 1 week, and 6 months. Assessments included Neuro-QoL and general and PD-specific validity measures.
Participants were 62% male and 95% white (average age = 66); H & Y stages were 1 (16%), 2 (61%), 3 (18%), and 4 (5%). Internal consistency and test-retest reliability of Neuro-QoL ranged from Cronbach's alphas = 0.81 to 0.94 with intraclass correlation coefficients = 0.66 to 0.80. Pearson's correlations between Neuro-QoL and legacy measures were generally moderate and in expected directions. UPDRS Part 2 was moderately correlated with Neuro-QoL Upper Extremity and Mobility, respectively (r's = -0.44; -0.59). Parkinson's Disease Questionnaire-39 and Neuro-QoL measures of similar constructs showed strong-to-moderate correlations (r's = 0.70-0.44). Neuro-QoL measures of fatigue, mobility, positive emotion, and emotional/behavioral control showed responsiveness to self-reported change.
Neuro-QoL is valid for use in PD clinical research. Reliability for all but two measures is sufficient for group comparisons, with some evidence supporting responsiveness to change. Neuro-QoL possesses characteristics, such as brevity, flexibility in administration, and suitability, for cross-disease comparisons that may be advantageous to users in a variety of settings. © 2016 Movement Disorder Society.
神经生活质量(Neuro-QoL)是一个多维度的患者报告结局测量系统,用于评估神经科患者及其照料者认为重要的身体、心理和社会健康方面。Neuro-QoL是最早使用现代测试开发方法创建的针对神经科的患者报告结局测量系统之一,它能够进行简短而精确的评估,并具备进行帕金森病(PD)特异性和跨疾病比较的能力。我们展示了使用PD患者样本对Neuro-QoL进行临床验证的结果。
从学术医疗中心招募了120名PD患者,在基线、1周和6个月时进行评估。评估包括Neuro-QoL以及一般和PD特异性效度测量。
参与者中男性占62%,白人占95%(平均年龄 = 66岁); Hoehn-Yahr(H&Y)分期为1期(16%)、2期(61%)、3期(18%)和4期(5%)。Neuro-QoL的内部一致性和重测信度范围为:Cronbach's α系数 = 0.81至0.94,组内相关系数 = 0.66至0.80。Neuro-QoL与传统测量指标之间的Pearson相关性一般为中等程度且符合预期方向。统一帕金森病评定量表(UPDRS)第2部分分别与Neuro-QoL上肢和运动功能呈中等程度相关(r值分别为 -0.44;-0.59)。帕金森病问卷-39(Parkinson's Disease Questionnaire-39)与Neuro-QoL中类似结构的测量指标显示出强至中等程度的相关性(r值 = 0.70 - 0.44)。Neuro-QoL中关于疲劳、运动功能、积极情绪和情绪/行为控制的测量指标显示出对自我报告变化的反应性。
Neuro-QoL可有效用于PD临床研究。除两项测量指标外,其他所有指标的信度足以进行组间比较,并有一些证据支持其对变化的反应性。Neuro-QoL具有简短、管理灵活以及适用于跨疾病比较等特点,这可能对各种环境中的使用者有利。© 2016运动障碍协会。